Literature DB >> 9209711

Recent update on the PPAR alpha-null mouse.

F J Gonzalez1.   

Abstract

Short-term treatment of rats and mice with peroxisome proliferators (PP) results in an increase in liver peroxisome number, marked hepatomegaly and induction of several genes encoding peroxisomal and other microsomal and mitochondrial enzymes involved in fatty acid metabolism. Chronic treatment of rodents with PP results in hepatocellular carcinoma. Species differences in PP responses have been found. For example, PP such as clofibrate and gemfibrozil, are highly effective lipid and cholesterol lowering drugs in humans but do not cause peroxisome proliferation and there is no evidence for increased liver cancers in patients receiving these drugs. A receptor, designated PP-activated receptor alpha (PPAR alpha) is capable of trans-activating reporter genes containing a PP response (PPRE), but requires the presence of both PP, 9-cis retinoic acid and another receptor called RXR alpha. However, PP may not directly bind to PPAR alpha but probably indirectly disturb cellular metabolism to liberate an endogenous ligand. Subsequent to the first identification of a PPAR alpha, other members of this receptor family were found and designated PPAR alpha, PPAR beta (also called NUC1 and PPAR delta) and PPAR gamma. The alpha form is most abundant in liver and kidney, sites of peroxisome proliferation while the other two receptors are not significantly expressed in these tissues. On the basis of tissue-specific localization and spectrum of target gene activation, the physiological function of PPAR alpha and PPAR gamma appear to be related to fatty acid metabolism and regulation of adipogenesis, respectively. To gain insight into the function of PPAR alpha and its role in the peroxisome proliferator response and hepatocellular carcinogenesis, gene targeting was used to develop a PPAR alpha-deficient mouse. These animals are resistant to the pleiotropic effects of PP and no induction of any known target gene has been found. Recent studies on the phenotypes of these mice have led to an understanding of the mechanism of action of PP. They have also provided a useful model to establish the physiological role of PPAR alpha in fatty acid homeostasis and inflammation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209711     DOI: 10.1016/s0300-9084(97)81506-4

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  16 in total

1.  Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.

Authors:  T Yamauchi; H Waki; J Kamon; K Murakami; K Motojima; K Komeda; H Miki; N Kubota; Y Terauchi; A Tsuchida; N Tsuboyama-Kasaoka; N Yamauchi; T Ide; W Hori; S Kato; M Fukayama; Y Akanuma; O Ezaki; A Itai; R Nagai; S Kimura; K Tobe; H Kagechika; K Shudo; T Kadowaki
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 2.  Peroxisome proliferator-activated receptors.

Authors:  Ouliana Ziouzenkova; Stephane Perrey; Niko Marx; Daniel Bacqueville; Jorge Plutzky
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 3.  PPARα signaling in the hippocampus: crosstalk between fat and memory.

Authors:  Avik Roy; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-10       Impact factor: 4.147

4.  Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.

Authors:  Yoshiyuki Takahara; Mitsuo Takahashi; Hiroki Wagatsuma; Fumihiko Yokoya; Qing-Wei Zhang; Mutsuyo Yamaguchi; Hiroyuki Aburatani; Norifumi Kawada
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

5.  Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver.

Authors:  Cécile Michel; Chantal Desdouets; Béatrice Sacre-Salem; Jean-Charles Gautier; Ruth Roberts; Eric Boitier
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

6.  PPARdelta is a very low-density lipoprotein sensor in macrophages.

Authors:  Ajay Chawla; Chih-Hao Lee; Yaacov Barak; Weimin He; John Rosenfeld; Debbie Liao; Jungyeob Han; Heonjoong Kang; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-22       Impact factor: 11.205

7.  Circulating free fatty acids are increased independently of PPARgamma activity after administration of poloxamer 407 to mice.

Authors:  Thomas P Johnston; David J Waxman
Journal:  Can J Physiol Pharmacol       Date:  2008-09       Impact factor: 2.273

8.  Peroxisome proliferator-activated receptor alpha is not the exclusive mediator of the effects of dietary cyclic FA in mice.

Authors:  Lionel Bretillon; Stefan E H Alexson; Florent Joffre; Bruno Pasquis; Jean-Louis Sébédio
Journal:  Lipids       Date:  2003-09       Impact factor: 1.880

9.  Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice.

Authors:  Qingmin Guo; Guangming Wang; Shobu Namura
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-02       Impact factor: 6.200

10.  The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.

Authors:  M C Thomas; K A Jandeleit-Dahm; C Tikellis
Journal:  PPAR Res       Date:  2012-02-12       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.